“Epirubicin and Docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: results from two successive phase II studies”, Radiol Oncol, vol. 47, no. 1, Apr. 2013, Accessed: Oct. 26, 2026. Available: https://radioloncol.com/index.php/ro/article/view/728